Skip to search formSkip to main contentSkip to account menu

QLT091001

National Institutes of Health

Related topics

Related topics

1 relation
retinol acetate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Outer Segment Thickness Predicts Visual Field Response to QLT091001 in Patients with RPE65 or LRAT Mutations.
PURPOSE To determine whether the degree of change in Goldmann visual fields (GVFs) following oral administration of QLT091001 was… 
2015
2015
Vision Improvement After Retreatment with an Oral Synthetic cis-Retinoid (QLT091001) in Subjects with LCA or RP due to Mutations in RPE65 or LRAT
2015
2015
Clinical Proof-of-Concept Study of Oral Synthetic cis-Retinoid (QLT091001) In Adult Subjects With Impaired Dark Adaptation and/or Impaired Low Luminance Vision
2013
2013
SD-OCT May Predict Response to QLT091001 in Patients with LCA or RP associated with RPE65 or LRAT Mutations
2012
2012
Oral Synthetic cis retinoid (QLT091001) treatment improves visual performance in an Leber Congenital Amaurosis (LCA) mouse model
Review
2011
Review
2011
FDA Pipeline Preview, January 2011 (Ezogabine, Ticagrelor, Naltrexone SR/bupropion, Clostridium difficile vaccine, Elacytarabine, Glycerol phenylbutyrate, Perifosine, Cladribine Tablets, Florbetapir…
Recent FDA action (through, December 2010) related to Ezogabine, Ticagrelor, Naltrexone SR/bupropion, Clostridium difficile… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)